Annual growth in global revenue for prescribed orphan drugs 2011-2024

Global prescription orphan drug annual growth in revenues from 2011 to 2024

Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

April 2019

Region

Worldwide

Survey time period

as of April 2019

Supplementary notes

Products that have orphan and non-orphan drug designations and are expected to generate less than 50% of their sales in 2018 and 2024 from their orphan-designated indication/s, are excluded from this analysis. This has led to the exclusion of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade.
* From 2019 on projected.

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Other statistics that may interest you

Other statistics that may interest you Statistics on

About the industry

9

About the region

10

Selected statistics

6

Other regions

10

Related statistics

10

Further related statistics

9
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.